Constitutively, activated ALK synergizes with MYCN overexpression in inducing neuroblastoma in animal models, and the co-occurrence of ALK F1174 mutations and MYCN amplification defines a subset of neuroblastoma patients with particularly poor outcome (Berry et al., 2012; Heukamp et al., 2012; Zhu et al., 2012). Here, ALK is linked to neuroblastoma.